isavuconazole and Brain-Diseases

isavuconazole has been researched along with Brain-Diseases* in 1 studies

Other Studies

1 other study(ies) available for isavuconazole and Brain-Diseases

Article	Year
Successful isavuconazole salvage therapy in a patient with invasive mucormycosis. Infection, 2014, Volume: 42, Issue:2 A 45-year-old male with rhinocerebral mucormycosis (Rhizopus oryzae), refractory to liposomal amphotericin B and posaconazole, received isavuconazole salvage therapy. Initial isavuconazole plasma and tissue levels were 0.76-0.86 μg/mL and 1.09-1.38 μg/g. Plasma levels increased to 1.3-3.24 μg/mL with reduced comedication. Isavuconazole was well tolerated, and the patient has remained disease-free 24 months post-antifungal therapy. Topics: Antifungal Agents; Brain Diseases; Humans; Male; Middle Aged; Mucormycosis; Nitriles; Pyridines; Rhizopus; Salvage Therapy; Treatment Outcome; Triazoles	2014

Article

Year

Successful isavuconazole salvage therapy in a patient with invasive mucormycosis.

Infection, 2014, Volume: 42, Issue:2

A 45-year-old male with rhinocerebral mucormycosis (Rhizopus oryzae), refractory to liposomal amphotericin B and posaconazole, received isavuconazole salvage therapy. Initial isavuconazole plasma and tissue levels were 0.76-0.86 μg/mL and 1.09-1.38 μg/g. Plasma levels increased to 1.3-3.24 μg/mL with reduced comedication. Isavuconazole was well tolerated, and the patient has remained disease-free 24 months post-antifungal therapy.

Topics: Antifungal Agents; Brain Diseases; Humans; Male; Middle Aged; Mucormycosis; Nitriles; Pyridines; Rhizopus; Salvage Therapy; Treatment Outcome; Triazoles

2014